Coherus Oncology, Inc.
For the period ended Sep 30, 2025. Filed Nov 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 6, 2025
CHRS$0.64-21.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity (Deficit
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · · · · · Accumulated · · · · · | |||||||||||||||||
| · · · · · · · Additional · · Other · · · · · Total | |||||||||||||||||
| · · Common Stock · · Paid-In · · Comprehensive · · Accumulated · · Stockholders' | |||||||||||||||||
| · Shares · · Amount · Capital · Loss · Deficit · Equity (Deficit) | |||||||||||||||||
| Balances at December 31, 2024 | 115,614,548 | | $12 | | $1,419,266 | | $(275) | | $(1,550,993) | | $(131,990) | ||||||
| Net loss | | — | | — | | — | | — | | (56,569) | | (56,569) | |||||
| Issuance of common stock upon vesting of restricted stock units ("RSUs") | | 474,410 | | — | | — | | — | | — | | — | |||||
| Taxes paid related to net share settlement of RSUs | | (181,742) | | | — | | | (264) | | | — | | | — | | | (264) |
| Stock-based compensation expense | | — | | — | | 5,353 | | — | | — | | 5,353 | |||||
| Balances at March 31, 2025 | 115,907,216 | | | 12 | | | 1,424,355 | | | (275) | | | (1,607,562) | | | (183,470) | |
| Net income | — | | — | | — | | — | | 297,767 | | 297,767 | ||||||
| Issuance of common stock upon vesting of RSUs | | 44,556 | | — | | — | | — | | — | | — | |||||
| Taxes paid related to net share settlement of RSUs | | (16,519) | | | — | | | (16) | | | — | | | — | | | (16) |
| Issuance of common stock under the employee stock purchase plan ("ESPP") | 287,473 | | — | | 188 | | — | | — | | 188 | ||||||
| Stock-based compensation expense | — | | — | | 5,358 | | — | | — | | 5,358 | ||||||
| Balances at June 30, 2025 | 116,222,726 | | | 12 | | | 1,429,885 | | | (275) | | | (1,309,795) | | | 119,827 | |
| Net loss | — | | | — | | | — | | | — | | | (35,531) | | (35,531) | ||
| Issuance of common stock upon exercise of stock options | | 7,000 | | | — | | | 5 | | | — | | | — | | 5 | |
| Issuance of common stock upon vesting of RSUs | | 9,707 | | | — | | | — | | | — | | | — | | — | |
| Taxes paid related to net share settlement of RSUs | | (3,415) | | | — | | | (3) | | | — | | | — | | (3) | |
| Stock-based compensation expense | — | | | — | | | 3,404 | | | — | | | — | | 3,404 | ||
| Other comprehensive gain, net of tax | — | | | — | | | — | | | 72 | | | — | | 72 | ||
| Balances at September 30, 2025 | 116,236,018 | | $12 | | $1,433,291 | | $(203) | | $(1,345,326) | | $87,774 | ||||||
Condensed Consolidated Statements of Stockholders’ Deficit
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · · · · · Accumulated · · · · · | |||||||||||||||||
| · · · · · · · Additional · · Other · · · · · Total | |||||||||||||||||
| · · Common Stock · · Paid-In · · Comprehensive · · Accumulated · · Stockholders' | |||||||||||||||||
| · Shares · · Amount · Capital · Loss · Deficit · Deficit | |||||||||||||||||
| Balances at December 31, 2023 | 112,215,260 | | $11 | | $1,386,312 | | $(248) | | $(1,579,500) | | $(193,425) | ||||||
| Net income | — | | — | | — | | — | | 102,875 | | 102,875 | ||||||
| Issuance of common stock upon exercise of stock options | 174,651 | | — | | 291 | | — | | — | | 291 | ||||||
| Issuance of common stock upon vesting of RSUs | 741,213 | | — | | — | | — | | — | | — | ||||||
| Issuance of common stock under ATM Offering, net of issuance costs | | 650,005 | | | — | | | 1,507 | | | — | | | — | | | 1,507 |
| Taxes paid related to net share settlement of RSUs | | (284,275) | | | — | | | (745) | | | — | | | — | | | (745) |
| Stock-based compensation expense | — | | — | | 7,677 | | — | | — | | 7,677 | ||||||
| Other comprehensive loss, net of tax | — | | — | | — | | (24) | | — | | (24) | ||||||
| Balances at March 31, 2024 | 113,496,854 | | | 11 | | | 1,395,042 | | | (272) | | | (1,476,625) | | | (81,844) | |
| Net loss | — | | — | | — | | — | | (12,921) | | (12,921) | ||||||
| Issuance of common stock upon vesting of RSUs | | 21,583 | | — | | — | | — | | — | | — | |||||
| Issuance of common stock - partial payout of 2023 bonus in RSUs | | 1,976,750 | | | 1 | | | 4,407 | | | — | | | — | | | 4,408 |
| Offering costs associated with ATM Offering | | — | | | — | | | (52) | | | — | | | — | | | (52) |
| Taxes paid related to net share settlement of RSUs | | (767,971) | | | — | | | (1,711) | | | — | | | — | | | (1,711) |
| Issuance of common stock under the ESPP | 471,439 | | — | | 685 | | — | | — | | 685 | ||||||
| Stock-based compensation expense | — | | — | | 7,327 | | — | | — | | 7,327 | ||||||
| Balances at June 30, 2024 | 115,198,655 | | | 12 | | | 1,405,698 | | | (272) | | | (1,489,546) | | | (84,108) | |
| Net loss | — | | | — | | | — | | | — | | | (10,751) | | (10,751) | ||
| Issuance of common stock upon vesting of RSUs | | 22,915 | | | — | | | — | | | — | | | — | | — | |
| Taxes paid related to net share settlement of RSUs | | (8,163) | | | — | | | (10) | | | — | | | — | | | (10) |
| Stock-based compensation expense | — | | | — | | | 6,899 | | | — | | | — | | 6,899 | ||
| Other comprehensive loss, net of tax | — | | | — | | | — | | | (3) | | | — | | (3) | ||
| Balances at September 30, 2024 | 115,213,407 | | $12 | | $1,412,587 | | $(275) | | $(1,500,297) | | $(87,973) | ||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.